Particulate matter (PM) associated cardiorespiratory and vascular dysfunction (CaRVD) poses a significant global health burden. The World Trade Center (WTC) destruction on September 11, 2001 led to an intense deposition of particulate matter (WTC-PM) into aerodigestive system. WTC associated morbidities include respiratory, gastrointestinal, chronic rhinosinusitis, cancer, mental health concerns and more recently a focus has been on cardiovascular disease. This proposal will investigate the development of WTC-cardiorespiratory and vascular dysfunction (WTC-CaRVD) which is firmly within the purview of the James Zadroga 9/11 Health and Compensation Act. WTC-PM exposure causes heterogeneous obstructive airways disease (OAD) patterns, which include airway hyperreactivity (AHR) and loss of FEV1. Early diagnosis and therapeutic options are few, in part due to limited understanding of their pathogenesis. While pulmonary vascular changes are classically thought to occur due to the hypoxemia of late OAD, recent investigations show that vascular dysfunction occurs early in OAD. This vascular hypothesis of OAD postulates that pulmonary vasculature remodeling leads to loss of lung function. Early evidence of WTC-CaRVD includes increased prevalence of cardiovascular disease risk factors such as metabolic syndrome, elevated pulmonary artery/aorta ratio, and cardiovascular biomarkers (such as CRP). Murine models of WTC-PM exposure show inflammation, AHR both acutely and persistently and reflect what is seen in FDNY 1st responders. Airway and cardiac remodeling were also persistent features of WTC-PM exposure in the study team's murine models. Therefore, the study team will focus on Heme Oxygenase-1 (HO-1), a mediator of oxidative stress, known to stimulate collagen formation and is also induced after WTC-PM exposure. Furthermore, pathways and mechanisms of WTC-CaRVD warrant further study and are the focus of the 5-year proposal. The HYPOTHESIS is that WTC-PM exposure causes WTC-CaRVD mediated by HO-1. First responders with AHR will have features of WTC-CaRVD, and will demonstrate a unique biomarker profile compared to controls.
Study Type
OBSERVATIONAL
Enrollment
100
NYU Clinical & Translational Science Institute Clinical Research Center (CTSI CRC)
New York, New York, United States
RECRUITINGLevels of Heme Oxygenase-1 (HO-1)
All serum will be thawed once and assayed for biomarkers
Time frame: up to Day 365
Levels of Glutathione
All serum will be thawed once and assayed for biomarkers
Time frame: up to Day 365
Levels of Total Antioxidant Capacity (TAC)
All serum will be thawed once and assayed for biomarkers
Time frame: up to Day 365
Levels of Superoxide Dismutase (SOD)
All serum will be thawed once and assayed for biomarkers
Time frame: up to Day 365
Levels of Macrophage inflammatory protein-2 (MIP-2)
All serum will be thawed once and assayed for biomarkers
Time frame: up to Day 365
Levels of C-reactive protein (CRP)
All serum will be thawed once and assayed for biomarkers
Time frame: up to Day 365
Levels of fractional exhaled nitric oxide (FeNO)
FeNO will be quantified using NIOX VERO®
Time frame: up to Day 365
Score on St. George's Respiratory Questionnaire (SGRQ-C)
SGRQ-C is designed to assess how one's breathing is troubling a participant and how it affects one's life. The questionnaire consists of 14 questions. The total score range is 0-54; the higher the score, the worse the chest trouble.
Time frame: up to Day 365
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.